- Home
- TNXP vs SNTI Comparison
TNXP vs SNTI Comparison
Compare TNXP & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SNTI
- Stock Information
- Founded
- TNXP 2007
- SNTI 2016
- Country
- TNXP United States
- SNTI United States
- Employees
- TNXP N/A
- SNTI N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- SNTI Health Care
- Exchange
- TNXP Nasdaq
- SNTI Nasdaq
- Market Cap
- TNXP 15.1M
- SNTI 14.1M
- IPO Year
- TNXP N/A
- SNTI N/A
- Fundamental
- Price
- TNXP $0.14
- SNTI $2.24
- Analyst Decision
- TNXP Strong Buy
- SNTI
- Analyst Count
- TNXP 2
- SNTI 0
- Target Price
- TNXP $53.50
- SNTI N/A
- AVG Volume (30 Days)
- TNXP 35.9M
- SNTI 19.6K
- Earning Date
- TNXP 11-07-2024
- SNTI 11-11-2024
- Dividend Yield
- TNXP N/A
- SNTI N/A
- EPS Growth
- TNXP N/A
- SNTI N/A
- EPS
- TNXP N/A
- SNTI N/A
- Revenue
- TNXP $12,458,000.00
- SNTI $338,000.00
- Revenue This Year
- TNXP $62.53
- SNTI $254.47
- Revenue Next Year
- TNXP $26.17
- SNTI $169.66
- P/E Ratio
- TNXP N/A
- SNTI N/A
- Revenue Growth
- TNXP N/A
- SNTI N/A
- 52 Week Low
- TNXP $0.12
- SNTI $1.52
- 52 Week High
- TNXP $22.08
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- TNXP 29.54
- SNTI 37.17
- Support Level
- TNXP $0.12
- SNTI $2.05
- Resistance Level
- TNXP $0.21
- SNTI $2.46
- Average True Range (ATR)
- TNXP 0.02
- SNTI 0.25
- MACD
- TNXP 0.02
- SNTI -0.09
- Stochastic Oscillator
- TNXP 21.56
- SNTI 15.32
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.